Medicines

Discover all available medicines and treatments

v.01 BETA

Transforming research data into powerful knowledge graphs for life science researchers.

Product

Pricing
Case Studies

Support

Company

About
Blog
Privacy
Terms

Florbetapir F 18: Uses, Interactions, and Clinical Data

Florbetapir F 18

Brand: Amyvid

Radiopharmaceutical, Diagnostic Agent

Imaging AgentCentral Nervous System Agent

ApprovedPrescription Only

Overview

Florbetapir F 18 is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. It is a small molecule that binds specifically to beta-amyloid plaques, a hallmark of Alzheimer's disease.

Primary Use

For PET imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment being evaluated for Alzheimer’s Disease and other causes of cognitive decline.

Pharmacokinetics

Rapid, within minutes

Onset

110 minutes

Half-Life

N/A

Max Dose

Renal excretion

Metabolism

Side Effects

Anxiety

Back pain

Neck pain

Claustrophobia

Dizziness

Drug Interactions

None known

high risk

Outcome:

No clinically significant interactions have been reported.

Mechanism:

Unknown

AI Predictions & Insights

Innovation Forecast

Most likely new formulation: Improved sensitivity and specificity through novel radiotracers (Year: 2026, 80% confidence)

Regulatory Outlook

Based on current usage trends and ongoing research, there is a 70% likelihood of expanded indications for Florbetapir F 18 to include earlier detection of amyloid plaques in asymptomatic individuals within the next 5 years.